1-5 of 5
Yun Dai, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Joel G Turner, PhD, Trinayan Kashyap, MS, Jana L Dawson, BS, Juan A Gomez, BS, Alexis Bauer, BS, Steven Grant, MD, Yun Dai, PhD, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Yosef Landesman, PhD, Daniel M Sullivan, MD
Journal: Blood
Blood (2016) 128 (22): 3299.
https://doi.org/10.1182/blood.V128.22.3299.3299
Published: 2016
Journal Articles

Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma

Daniel M Sullivan, MD, Trinayan Kashyap, MS, Jana L Dawson, BS, Yosef Landesman, PhD, Steven Grant, MD, Kenneth H. Shain, MD PhD, Yun Dai, PhD, Michael Kauffman, MD PhD, Sharon Shacham, Joel G Turner, PhD
Journal: Blood
Blood (2015) 126 (23): 3048.
https://doi.org/10.1182/blood.V126.23.3048.3048
Published: 2015
Journal Articles

Next Generation XPO1 Inhibitor KPT-8602 for the Treatment of Drug-Resistant Multiple Myeloma

Joel G Turner, PhD, Jana L Dawson, BS, Christopher L Cubitt, PhD, Erkan Baluglo, PhD, Steven Grant, MD, Yun Dai, PhD, Kenneth H Shain, MD PhD, William S. Dalton, PhD MD, Sharon Shacham, William Senapedis, PhD, Daniel M Sullivan, MD
Journal: Blood
Blood (2015) 126 (23): 1818.
https://doi.org/10.1182/blood.V126.23.1818.1818
Published: 2015
Journal Articles

Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism

Xin-Yan Pei, MD, Michael W Sanderson, BS, Leena E Youssefian, M.S, Jessica Felthousen, BS, Lora B Kramer, BS, Yun Dai, PhD, Steven Grant, MD
Journal: Blood
Blood (2014) 124 (21): 4763.
https://doi.org/10.1182/blood.V124.21.4763.4763
Published: 2014
Journal Articles

Vorinostat Synergistically Potentiates MK-0457 Lethality in Chronic Myelogenous Leukemia (CML) Cells Sensitive and Resistant to Imatinib Mesylate.

Yun Dai, PhD, Shuang Chen, PhD/MD, Charis A. Venditti, MD, Tri K. Nguyen, PhD, Paul Dent, PhD, Steven Grant, MD
Journal: Blood
Blood (2007) 110 (11): 1041.
https://doi.org/10.1182/blood.V110.11.1041.1041
Published: 2007